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Abstract
Background: Accumulating data suggest a novel role for bile acids (BAs) in modulating metabolic homeostasis. BA
treatment has been shown to improve glucose tolerance and to increase energy expenditure in mice. Here, we
investigated the relationship between fasting plasma BAs concentrations and metabolic parameters in humans.
Findings: Fasting plasma glucose, insulin and lipid profile were measured in 14 healthy volunteers, 20 patients with
type 2 diabetes (T2D), and 22 non-diabetic abdominally obese subjects. Insulin sensitivity was also assessed by the
determination of the glucose infusion rate (GIR) during a hyperinsulinemic-euglycemic clamp in a subgroup of
patients (9 healthy and 16 T2D subjects). Energy expenditure was measured by indirect calorimetry. Plasma cholic
acid (CA), chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) concentrations were analyzed by gas
chromatograph-mass spectrometry. In univariable analysis, a positive association was found between HOMA-IR and
plasma CDCA (b = 0.09, p = 0.001), CA (b = 0.03, p = 0.09) and DCA concentrations (b = 0.07, p < 0.0001). Spearman
analysis retrieved an inverse relationship between plasma CDCA (r = -0.44, p = 0.03), CA (r = -0.65, p = 0.001) and the
GIR. HOMA-IR remained positively associated with CDCA (b = 0.11, p = 0.01), CA (b = 0.04, p = 0.01) and DCA (b =
0.06, p = 0.007) in multivariable analysis, after adjustment for age, gender, BMI, HbA1C and plasma lipid parameters.
In contrast, HbA1c, energy expenditure and plasma lipid concentrations were not correlated with plasma BAs levels
in multivariable analysis.
Conclusions: Both plasma CDCA, CA and DCA concentrations were negatively associated with insulin sensitivity in
a wide range of subjects.
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Background
Bile acids (BAs) and BA receptors emerge as new modu-
lators of glucose homeostasis [1]. FXR (farnesoid ×
receptor) is a nuclear receptor that controls BA and
lipid metabolism [2,3]. Several studies have highlighted
an unexpected role of FXR in metabolic homeostasis
[4,5]. While FXR-deficient mice exhibit insulin resis-
tance [6,7], treatment of ob/ob and db/db diabetic mice
with a synthetic FXR agonist improves blood glucose
levels as well as insulin sensitivity [6,8]. However, the
picture is more complex since FXR deficiency improves
glucose homeostasis and attenuates body weight gain in
an obese genetic background [9].
The addition of cholic acid (CA) to the diet increases
energy expenditure and prevents the development of
high fat-induced obesity and insulin resistance in mice
[10]. This metabolic effect of CA is mediated by the bind-
ing to the G-protein-coupled receptor TGR5 [11,12],
leading to the induction of the cAMP-dependent thyroid
hormone activation enzyme DIO2 (type 2 iodothyronine
deiodinase) in brown adipose tissue [10]. Human TGR5
is activated by several BAs, with lithocholic acid (LCA)
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ural agonists [12]. In addition, the activation of TGR5 by
a semi-synthetic specific agonist induces GLP-1 secretion
and improves glucose tolerance in mice [13].
The aim of the present study was to ascertain whether
plasma BA concentrations are linked to insulin sensitiv-
ity, assessed both by the homeostasis model assessment
(HOMA-IR) and the gold-standard hyperinsulinemic-
euglycemic clamp method, in a variety of subjects
including healthy volunteers, obese and type 2 diabetic
(T2D) patients.
Methods
Subjects
The baseline characteristics of the 56 participants involved
i nt h es t u d ya r ep r e s e n t e di nT a b l e1 .T h es t u d yg r o u p
consisted of 14 healthy lean volunteers, 22 obese subjects
and 20 patients with T2D. All the participants had no
acute pathology at the time of the clamp. Healthy volun-
teers and obese subjects did not take any medication. T2D
patients were under diet only or had discontinued their
anti-diabetic medications, but not hypolipidemic drugs,
at least 4 weeks before the clamp. They were asked to
consume a standardized isocaloric diet and to maintain a
normal physical activity during the 3 days before the
study. The patients were recruited in two centers: Human
Nutrition Research Center of Nantes (Center 1)a n d
Rhône-Alpes (Center 2). All participants gave their written
consent after being informed of the nature, purpose, and
possible risks of the study. The experimental protocols
were conducted before July 1, 2008, and were approved
by the ethical committees of the CHU de Nantes and
Hospices Civils de Lyon and performed according to
French legislation.
Study design
The study was conducted after a 12-h overnight fast. Fast-
ing plasma glucose and insulin were determined by the
glucose oxidase method (Glucose HK, Roche Diagnostics,
Meylan, France) and radioimmunoassay (bi-insulin IRMA,
Cisbio international, Gif-sur-Yvette, France). HbA1c was
measured by HPLC (TOSOH, A1C2.2 - G5). Plasma CA,
CDCA and DCA concentrations were analyzed by gas
chromatograph-mass spectrometry according to the
method of Stellaard F. et al. [14]. Insulin sensitivity was
also measured with the hyperinsulinemic-euglycemic
clamp technique according to DeFronzo et al [15]. Insulin
infusion rate was 40 mU/m
2.m i ni nt h eCenter 1 and
75 mU/m
2. min in the Center 2. Energy expenditure was
continuously measured during 30 min throughout the test
by open circuit indirect calorimetry (Deltatrac II, Datex
Instrument, Helsinki, Finland) under basal supine condi-
tion, before performing the clamp. The average gas
exchange recorded over the 30-min period was used to
calculate the basal metabolic rate.
Statistical analysis
Continuous variables are expressed as means and stan-
dard deviation and categorical variables as percent and
count. Analysis of variance (ANOVA) or Kruskal-Wallis
Table 1 Anthropometric, biochemical, and metabolic parameters of the studied groups
Control Obese T2D
n1 4 2 2 2 0
Age (yr) 45 [41;59] 49 [20;60] 55 [40;63]
#,$
Gender (males/females) 5/9 20/2 12/8
BMI (kg/m2) 23.85 [21.20;32.40] 33.60 [27.90;38.50] * 31.85 [22.80;39.10]
#
Fasting glucose (mg/dl) 5.03 [4.50;5.85] 5.50 [4.30;6.80] * 7.37 [5.11;12.50]
#,$
HbA1c (%) 5.40 [5.00;5.90] 5.45 [4.80;6.50] 7.40 [5.80;11.70]
#,$
Fasting insulin (μUI/ml) 5.90 [2.90;13.90] 11.55 [3.90;35.70] * 11.65 [2.10;38.40]
#
HOMA 1.33 [0.60;3.03] 3.15 [0.85;10.79] 3.85 [0.66;16.38]
#
BMR (kcal/24 h) 1368 [1066;1920] 1895 [1590;2350] * 1701 [1264;2062]
#,$
TC (mg/dl) 209 [170;292] 201[138;250] 184 [104;219]
#
TG (mg/dl) 90 [51;187] 140 [62;531] * 130 [44;335]
LDL-C (mg/dl) 122 [86;178] 131 [92;165] 112 [35;139]
#,$
HDL-C (mg/dl) 66 [40;103] 40 [26;54] * 46 [37;74]
#,$
Total BA (μmol/l) 1.06 [0.46;1.90] 1.49 [0.64;4.06]* 1.34 [0.53;5.54]
DCA (μmol/l) 0.38 [0.14;1.02] 0.44 [0.03;1.07] 0.62 [0.11;1.66]
#
CDCA (μmol/l) 0.36 [0.09;1.25] 0.60 [0.31;2.38] 0.43 [0.09;2.78]
CA (μmol/l) 0.22 [0.08;0.50] 0.35 [0.09;1.20] * 0.26 [0.1;1.10]
Data represent median [min;max]. Total BA represent the sum of DCA + CDCA + CA.
Tukey test was used for comparison of clinical parameters between the groups. Statistically significant differences (p < 0.05) are shown between controls and
obeses (*), control and type 2 diabetics (
#), and obeses and type 2 diabetics (
$).
HOMA: homeostasis model assessment (= glucose × insulin/22.5), BMR: basal metabolic rate, TC: total cholesterol, TG: triglycerides, DCA: deoxycholic acid, CDCA:
chenodeoxycholic acid, CA: cholic acid.
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among 3 groups. If ANOVA showed a significant differ-
ence between the groups, Tukey test was used for com-
parison of clinical parameters between two groups.
Categorical variables were compared by chi-square test.
Linear simple and multiple regression analyses were per-
formed for estimation of association between plasma
bile acids concentrations and metabolic parameters. All
factors were included in linear multiple regression ana-
lyses. Spearman coefficients were used for correlation
between plasma BA levels and GIR. A p value ≤ 0.05
was considered statistically significant. Statistical analysis
was performed with SAS for Windows version 9.1 soft-
ware (SAS Institute Inc, Cary, NC, USA).
Results
Circulating bile acids and glucose homeostasis
Total plasma BAs concentrations were higher in both
obese and T2D in comparison with the healthy controls,
but the difference reached statistical significance only
for the obese subjects compared to controls (Table 1).
Plasma DCA was significantly higher in T2D compared
to control group, while plasma CA was significantly
increased in obese patients compared to controls.
Linear simple regression analyses (Table 2) indicated
that plasma BAs concentrations negatively correlated with
insulin sensitivity. Indeed, DCA, CDCA and CA plasma
concentrations were positively associated with fasting
plasma insulin levels and HOMA-IR. To further assess
insulin sensitivity with the gold standard method, we mea-
sured the GIR during a hyperinsulinemic-euglycemic
clamp. Importantly, the GIR was inversely associated with
plasma CDCA (r = -0.36, p = 0.05 for Center 1; r = -0.44,
p=0 . 0 3f o rCenter 2) and CA (r = -0.38, p = 0.04 for Cen-
ter 1; r = -0.65, p = 0.001 for Center 2) levels; while the
negative correlation with the DCA did not reach statistical
significance (r = -0.30, p = 0.10 for Center 1; r = -0.35, p =
0.08 for Center 2) (Figure 1A-B). Except for a positive cor-
relation between DCA and fasting blood glucose levels, no
association was detected between BAs and the glycaemic
status (Table 2).
To further assess the strength of the correlation
between circulating BAs levels and insulin sensitivity, a
multiple regression analysis was performed (Table 3).
The positive correlation of plasma BAs concentrations
with HOMA-IR remained significant after adjustment for
each categorical variable: CDCA (b = 0.116, p = 0.01),
CA (b = 0.045, p = 0.01) DCA (b =0 . 0 6 2 ,p=0 . 0 0 7 ) .I n
contrast, plasma BAs levels were neither associated with
fasting plasma glucose nor the HbA1c.
Circulating bile acids and energy expenditure
A slight positive correlation was found between plasma
CDCA and CA concentrations and the basal metabolic
rate (BMR) in simple regression analysis (Table 2).
However, plasma BAs concentrations were not found to
be independently associated with BMR in multiple
regression analysis (Table 3). Although a significant
positive relationship was identified between plasma
DCA and CDCA levels and BMI in simple regression,
no further significant association between the BMI and
plasma BAs levels was found in multiple regression
analysis.
Discussion
Besides their role as detergent molecules, BAs appear to
modulate a broad spectrum of metabolic pathways includ-
ing lipid and glucose homeostasis [1]. These findings are
mainly based on animal studies and the clinical impact of
BAs on metabolic homeostasis remains to be determined
in human. Here, we show that plasma CDCA, CA and
DCA concentrations were negatively associated with insu-
lin sensitivity in a variety of subjects, including healthy
volunteers, obese and T2D patients. In contrast, plasma
Table 2 Linear simple regression analysis on plasma bile acid concentrations and variables
DCA CDCA CA
b 95% confidence
interval
p-value b 95% confidence
interval
p-value b 95% confidence
interval
p-value
Age 0.01 [0.002;0.02] 0.02 0.001 [-0.02;0.02] NS 0.004 [-0.003;0.01] NS
Men 0.002 [-0.19;0.19] NS 0.39 [0.04;0.74] 0.03 0.17 [0.03;0.31] 0.02
BMI 0.02 [0.0006;0.04] 0.04 0.04 [0.004;0.07] 0.03 0.01 [-0.003;0.03] NS
Fasting
glucose
0.8 [0.03;0.12] 0.001 0.05 [-0,04;0.14] NS 0.03 [-0.03;0.04] NS
Fasting
insulin
0.02 [0.01;0.03] < 10
-4 0.04 [0.02;0.06] 0.001 0.02 [0.006;0.02] 0.001
HbA1C 0.04 [-0.03;0.12] NS -0.05 [-0.18;0.08] NS -0.04 [-0.09;0.02] NS
HOMA-R 0.07 [0.04;0.19] < 10
-4 0.09 [0.04;0.14] 0.001 0.03 [0.007;0.05] 0.09
BMR 0.0001 [-0.0002;0.0004] NS 0.0008 [0.0002;0.001] 0.01 0.0002 [2.4*10
-7 ;0.0005] 0.05
Linear simple regression analyses were performed for estimation of association between plasma BAs concentrations and metabolic parameters. A p value ≤ 0.05
was considered statistically significant.
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tus. Importantly, HOMA-IR remained positively related to
those plasma BAs levels in multivariable analysis. When
assessing insulin sensitivity by the clamp procedure, we
further observed an inverse relationship between plasma
CDCA and CA concentrations and insulin sensitivity (i.e.
GIR).
Our data sustain the hypothesis for a role of plasma
BAs and FXR in insulin resistance. FXR-deficient mice,
which exhibit high plasma BA concentrations [2,3], dis-
play impaired peripheral insulin sensitivity [6,7]. Conver-
sely, treatment with synthetic specific FXR agonists
improved insulin sensitivity in rodents [6,8], and in
patients with non-alcoholic fatty liver disease [16]. Pre-
vious studies have suggested a link between BA pool size
and glucose metabolism in humans. In a study performed
in 6 Pima Indians with T2D, the BA pool was found to be
increased during untreated hyperglycaemia and conver-
sely decreased upon insulin therapy [17]. In contrast, the
BA pool size remained unaltered upon insulin treatment
in another study involving 14 patients with T2D [18].
Very recently, a well-designed study has retrieved an
increase in the DCA absolute pool size, without change
in total pool size in patients with T2D [19]. Accordingly,
plasma DCA levels were significantly increased in T2D
patients in comparison with controls in the present
study. In lipid-lowering trials, BA sequestrants, which
disrupt the enterohepatic circulation of BAs, have been
shown to lower plasma glucose and HbA1c [20]. How-
ever, the changes in BA metabolism following coleseve-
lam treatment were not related to changes in glucose
metabolism in patients with T2D [19]. In contrast, a
metabolomic study in healthy and pre-diabetic indivi-
duals found a correlation between plasma BAs levels and
insulin sensitivity [21]. Thus, additional studies using
FXR or TGR5 agonists are needed to unravel the effect of
BAs on insulin sensitivity in human.
In mice, plasma BAs increase energy expenditure via a
TGR5-mediated signalling cascade in brown adipose tissue
[10]. This pathway has been suggested to operate in
human skeletal myocytes [10], but its clinical relevance has
been challenged recently [22]. Here, we found a slight posi-
tive correlation between CDCA and CA plasma levels and
energy expenditure. In contrast, plasma levels of DCA, one
o ft h eb e s tl i g a n do fT G R 5[ 1 2 ] ,d i dn o ta s s o c i a t ew i t h
BMR. Moreover, circulating BAs failed to correlate with
energy expenditure in multivariable regression analysis.
One limitation of our study is that all the components of
diabetic control
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Figure 1 Spearman correlation of plasma bile acids concentrations and insulin sensitivity in healthy controls (n = 14) (black triangle),
type 2 diabetic (black square) (n = 20) and obese (white diamond) (n = 22) subjects. Plasma chenodeoxycholic acid (CDCA) and cholic
acid (CA) concentrations were measured by GC-MS analysis. Insulin sensitivity was assessed by the rate of infused glucose necessary to maintain
euglycaemia during infusion of insulin (GIR: glucose infusion rate). In the center 2 (A), the insulin infusion rate was 75 mU/m
2, while it was 40
mU/m
2 in the center 1 (B).
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Page 4 of 6the plasma BA profile were not analyzed. Thus, we can not
exclude that some low abundant plasma BA species (for
instance, LCA) might affect insulin sensitivity or energy
expenditure.
In summary, we found that plasma CDCA and CA,
and in a lesser extent DCA, were related to insulin resis-
tance in a wide range of subjects. These data sustain the
hypothesis for a role of BAs in glucose homeostasis.
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